Connect with us

Business

South Africa suspends AstraZeneca vaccine drive – CTV News

Published

 on


JOHANNESBURG —
South Africa has suspended plans to inoculate its front-line health care workers with the Oxford-AstraZeneca vaccine after a small clinical trial suggested that it isn’t effective in preventing mild to moderate illness from the variant dominant in the country.

South Africa received its first 1 million doses of the AstraZeneca vaccine last week and was expected to begin giving jabs to health care workers in mid-February. The disappointing early results indicate that an inoculation drive using the AstraZeneca vaccine may not be useful.

Preliminary data from a small study suggested that the AstraZeneca vaccine offers only “minimal protection against mild-moderate disease” caused by the variant in South Africa. The variant appears more infectious and is driving a deadly resurgence of the disease in the country, currently accounting for more than 90% of the COVID-19 cases, health minister Zweli Mkhize said Sunday night.

“The AstraZeneca vaccine appeared effective against the original strain, but not against the variant,” Mkhize said. “We have decided to put a temporary hold on the rollout of the vaccine … more work needs to be done.”

The study, which hasn’t yet been peer-reviewed, involved 2,000 people, most of whom were young and healthy. The volunteers’ average age was 31.

“Protection against moderate-severe disease, hospitalization or death could not be assessed in this study as the target population were at such low risk,” said a statement issued by Oxford University and the University of the Witwatersrand in Johannesburg.

Scientists will be studying whether or not the AstraZeneca vaccine is effective in preventing severe disease and death against the variant, Mkhize said.

Other vaccines have shown reduced efficacy against the variant, but have provided good protection from serious disease and death.

Public health officials are concerned about the South Africa variant because it contains a mutation of the virus’ characteristic spike protein, which is targeted by existing vaccines. South African officials say the variant is more contagious and evidence is emerging that it may be more virulent.

South Africa will urgently roll out other vaccines to inoculate as many as possible in the coming months, Mkhize said. Other South African scientists on Sunday said the clinical trials for the Johnson & Johnson vaccine show good results against the variant.

The early results for the AstraZeneca vaccine against the variant could have far-reaching implications as many other countries in Africa and beyond have been planning to use the AstraZeneca shot. The international COVAX initiative has bought the AstraZeneca vaccine in bulk from the Serum Institute of India.

Developers of the Oxford-AstraZeneca vaccine expect to have a modified jab to cope with the South Africa coronavirus variant by autumn, the vaccine’s lead researcher said Sunday.

Sarah Gilbert, lead researcher for the Oxford team, told the BBC on Sunday that “we have a version with the South African spike sequence in the works.”

“It looks very likely that we can have a new version ready to use in the autumn,” she added.

Authorities in England last week went house-to-house to administer COVID-19 testing in eight areas where the South Africa variant is believed to be spreading, after a handful of cases were found in people who had no contact with the country or anyone who travelled there.

More than 100 cases of the South African variant have been found in the U.K. The testing blitz is a bid to snuff out the variant before it spreads widely and undermines the U.K.’s vaccination rollout.

Britain has seen Europe’s deadliest coronavirus outbreak, with over 112,000 confirmed deaths, but it has embarked on a speedier vaccination plan than the neighbouring European Union. So far, the U.K. has given a first coronavirus vaccine jab to about 11.5 million people.

Let’s block ads! (Why?)



Source link

Continue Reading

Business

COVID-19: National panel agrees with Dr. Henry on four-month vaccine delay – Vancouver Sun

Published

 on


The vaccine experts say extending the dose interval to four months can protect the entire adult population within a short time despite limited supply.

Article content

Taking a cue from B.C.’s top doctor, a national panel of vaccine experts recommended that provinces extend the interval between the two doses of a COVID-19 shot to up to four months when faced with a limited supply, in order to quickly immunize as many people as possible.

The National Advisory Committee on Immunization issued updated guidance Wednesday for the administration of all COVID-19 vaccines currently approved for use in Canada.

Extending the dose interval to four months will create opportunities to protect the entire adult population against the virus within a short time frame, the panel said in releasing the recommendation.

As many as 80 per cent of Canadians over 16 could receive a single dose by the end of June simply with the expected supply of Pfizer-BioNTech and Moderna vaccines, the panel said.

  1. The British Columbia Centre for Disease Control says new preliminary data shows that a single dose of a COVID-19 vaccine reduces the risk of the virus by 80 per cent within two to three weeks of receiving the shot. The agency says in a statement that research led by Dr. Danuta Skowronski, the head of its influenza and emerging respiratory pathogens team shown here in a file photo, came to the conclusion after analyzing COVID-19 cases in long-term care homes.

    A look at the studies from Israel, U.K. that informed B.C.’s second-dose delay

  2. B.C. provincial health officer Dr. Bonnie Henry.

    Longer interval between doses means restrictions can be lifted sooner: Henry

The addition of the newly approved Oxford-AstraZeneca vaccine to the country’s supply could mean almost all Canadians would get their first shot in that time frame, but the federal government has not yet said how many doses of that vaccine will be delivered in the spring and how many in the summer.

Article content

“The vaccine effectiveness of the first dose will be monitored closely and the decision to delay the second dose will be continuously assessed based on surveillance and effectiveness data and post-implementation study designs,” the panel wrote.

“Effectiveness against variants of concern will also be monitored closely, and recommendations may need to be revised,” it said, adding there is currently no evidence that a longer interval will affect the emergence of the variants.

The committee’s recommendation came hours after Newfoundland and Labrador said it will extend the interval between the first and second doses to four months, and days after B.C. health officer Dr. Bonnie Henry announced the province was doing so.

Manitoba also said Wednesday it will delay second doses in order to focus on giving the first shot to more people more quickly.

Ontario previously said it was weighing a similar move but would seek advice from the federal government.


Get the latest COVID-19 news delivered to your inbox weeknights at 7 p.m. by subscribing to our newsletter here.


CLICK HERE to report a typo.

Is there more to this story? We’d like to hear from you about this or any other stories you think we should know about. Email vant

Let’s block ads! (Why?)



Source link

Continue Reading

Business

Trudeau 'very optimistic' vaccine rollout can be accelerated and move closer to U.S. goals – National Post

Published

 on


Trudeau held to his September target, but said with vaccine deliveries being moved up and new candidates being approved, the timeline could be moved up

Article content

OTTAWA – Prime Minister Justin Trudeau said Wednesday morning he was hopeful Canada’s vaccine timelines could be moved up, but offered no assurance the vaccine rollout here won’t be completed months after the United States.

But late on Wednesday afternoon, a national panel of vaccine experts recommended extending the interval between the two doses of a COVID-19 shot when faced with a limited supply.

Canada’s National Advisory Committee on Immunization’s updated guidance is for the administration of all COVID-19 vaccines currently approved for use in Canada. It says extending the dose interval to four months will create opportunities to protect the entire adult population against the virus within a shorter timeframe.

U.S. President Joe Biden said Tuesday evening America would have enough vaccines delivered to cover the entire population by late May. The rollout of those vaccines into arms will follow, but America is still likely to be able to vaccinate its entire population months ahead of Canada.

Advertisement

Story continues below

This advertisement has not loaded yet, but your article continues below.

Article content

Trudeau’s long-held timeline is to have all Canadians vaccinated by the end of September. He held to that target at his Wednesday morning press conference, but said with vaccine deliveries being moved up and new candidates being approved, it is possible the timeline could be moved up.

“We’re very optimistic that we’re going to be able to accelerate some of these timelines,” he said. “We’re going to continue to do everything we can to allow our population to get through this challenge as quickly as possible,” he said.

  1. Public health measures like masking are being recommended regardless of if someone has been vaccinated.

    What happens after my COVID shots? Masking, social-distancing, still recommended, but some experts want different approach

  2. Federal Procurement Minister Anita Anand.

    Liberals confident U.S. AstraZeneca vaccines will be delivered despite Biden’s ‘America first’ strategy

Trudeau said COVID has had a much more devastating impact on the U.S. and that will have a significant impact on the recovery.

“Obviously, the pandemic has had a very different course in the United States with far greater death tolls and case counts and that has had its own impact on the American economy,” he said.

Conservative MP Michelle Rempel Garner, the party’s health critic, said the government should be providing a clearer, more detailed explanation of its vaccine plan, to help businesses have confidence about what comes next.

“We don’t have any of that data. We don’t actually know what the realistic time horizon is for delivery of vaccines,” she said.

With Canada set to be months behind the U.S., United Kingdom and potentially other countries in the rollout, Rempel Garner said the government should be offering information about what else it will do to ease the pandemic in the meantime.

Advertisement

Story continues below

This advertisement has not loaded yet, but your article continues below.

Article content

“I think we’ll have a problem on compliance and certainty for business reopening, so this is why we’re saying look, be honest with Canadians, and then let’s work together to come up with a plan B,” she said. “COVID fatigue is a real thing. There’s a lot of frustration.”

Trudeau announced that both the government’s rent subsidy for small business and the wage subsidy will be extended into June as the pandemic continues. The extension of the rent subsidy is forecasted to cost an additional $2.1 billion and the wage subsidy will cost the government an additional $13.9 billion.

Finance Minister Chyrstia Freeland said the government would continue to support businesses with the goal of keeping the economy moving so it can resurge quickly when restrictions are lifted.

“Our government will continue to do whatever it takes for as long as it takes to help Canadians through this bleak time, to prevent economic scarring and invest in a way that allows us all to come roaring back,” she said.

Biden moved up his timeline to May, from what had been the end of July, after announcing the U.S. government had approved a third vaccine candidate from Johnson and Johnson. Canada is expected to approve that vaccine soon.

Canada received 500,000 doses of the AstraZeneca vaccine, the first shipment in a total of two million doses expected before mid-May, on top of a further 20 million doses expected between April and September.

Despite all the recent vaccine announcements, Trudeau said it was too early to formally move up the deadline, because there could still be issues with manufacturing or deliveries.

Advertisement

Story continues below

This advertisement has not loaded yet, but your article continues below.

Article content

“These are new processes for new vaccines that are being manufactured in the millions and even billions in order to cover everyone on Earth,” he said. “We’ll be facing continued challenges, which is one of the reasons why we made such a deliberate effort to sign more deals with more different companies than many of our fellow countries.”

While the Biden administration has said it won’t ship vaccines from the U.S. to other countries until all Americans are vaccinated, Trudeau said Biden knows the challenge is global.

“It was very clear that they understand, like us, we know that you don’t get through this pandemic, anywhere, not fully, until you get through it everywhere.”

— With files from The Canadian Press

• Email: rtumilty@postmedia.com | Twitter:

Comments

Postmedia is committed to maintaining a lively but civil forum for discussion and encourage all readers to share their views on our articles. Comments may take up to an hour for moderation before appearing on the site. We ask you to keep your comments relevant and respectful. We have enabled email notifications—you will now receive an email if you receive a reply to your comment, there is an update to a comment thread you follow or if a user you follow comments. Visit our Community Guidelines for more information and details on how to adjust your email settings.

Let’s block ads! (Why?)



Source link

Continue Reading

Business

Nova Scotia to accept shipment of AstraZeneca's COVID-19 vaccine – HalifaxToday.ca

Published

 on


Nova Scotia has decided to receive its first shipment of the Oxford-AstraZeneca vaccine.

Next week, the province will get 13,000 doses of the third COVID-19 vaccine approved for use by Health Canada.

They don’t have a long shelf life and must be used by April 2.

Because of that, even though it is a two dose vaccine, the province announced today it plans to administer all of the supply as first doses. They will be going into the arms of Nova Scotians between the ages of 50 and 64 at 26 locations throughout the province on a first-come, first-served basis.

Earlier this week, the National Advisory Committee on Immunization recommended the Oxford-AstraZeneca only be used for people between the ages of 18 and 64.

“AstraZeneca is different than the two vaccines we’re using now,” explained the province’s chief medical officer of health at Tuesday’s briefing. “The Pfizer-BioNtech and the Moderna are mRNA vaccines, which have been shown to be 94 to 95 per cent effective in preventing symptomatic COVID-19 illness.”

“The AstraZeneca is slightly different. It’s called a viral-vector vaccine and it’s been shown to be about 62 per cent effective against preventing symptomatic illness.”

Because of that, Dr. Robert Strang said it won’t be used for any group considered to be a high risk for severe disease and/or exposure.

Unlike the mRNA vaccines, the Oxford-AstraZeneca vaccine does contain a virus, however the province says it isn’t the one that causes COVID-19. It’s a “different, harmless virus that triggers an immune response.”

The vaccine also doesn’t need the cold or ultra-low cold storage that the other two require. It can be stored between 2 and 8 degrees Celsius, which is similar to the standard flu vaccine.

Doctors Nova Scotia and the Pharmacy Association of Nova Scotia will be handling the launch.

“This vaccine provides another tool in our fight against COVID-19 and builds on the roll-out that is already underway in our province as we work to vaccinate all Nova Scotians,” said Premier Iain Rankin in a news release. “We have to move fast as we are mindful of the fact that we have a short window to use it given that they will expire in a month.”

Let’s block ads! (Why?)



Source link

Continue Reading

Trending